Literature DB >> 34268086

Diagnostic value of puncture feeling combined with BRAF V600E mutation in repeat US-FNA biopsy of Bethesda III thyroid nodules.

Li Li1,2, Peipei Li2, Xiao Chen2, Lin Kang3, Yuquan Ye1,2.   

Abstract

BACKGROUND: The diagnosis and treatment of Bethesda III thyroid nodules has always been controversial. Our aim is to study the value of puncture feeling combined with BRAF V600E mutation detection in the diagnosis of Bethesda III thyroid nodules in repeat fine needle aspiration (FNA).
METHODS: From January 1, 2017 to December 31, 2021, a total of 1,114 thyroid nodules were included, of which Bethesda III thyroid nodules accounted for 12.1%. We analyzed the correlation between puncture feeling and postoperative pathology. Then, the diagnostic value of puncture feeling in Bethesda III thyroid nodules and the mutation rate of BRAF V600E in repeated FNA and its correlation with puncture feeling were analyzed.
RESULTS: The results showed that there was a significant correlation between puncture feeling and postoperative pathology in the 1114 thyroid nodules (P<0.001). Additionally, 93.4% (299/320) of the thyroid nodules with soft puncture feeling were benign, 89.0% (460/517) of the thyroid nodules with hard puncture feeling were malignant, and 93.1% (258/277) of the thyroid nodules with a puncture feeling of hard with grittiness were malignant. There was high consistency of puncture feelings among different operators (P<0.001). The distribution of puncture feeling between benign and malignant thyroid nodules was significantly different (P<0.001) in Bethesda III thyroid nodules. In the puncture feeling ROC curve of Bethesda III thyroid nodules based on pathology, the AUC was 0.895 (95% CI: 0.817-0.973, P<0.001). In repeat FNA, BRAF V600E was significantly correlated with puncture feeling (P<0.001). BRAF V600E mutation was found in 22 (68.8%) malignant nodules.
CONCLUSIONS: Puncture feelings of hard and hard with grittiness were malignant risk factors. Repeated FNA and BRAF V600 mutation detection should be performed for Bethesda III thyroid nodules with a hard or hard with grittiness puncture feeling. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  BRAF V600E; Bethesda III thyroid nodules; benign; malignant; puncture feeling

Year:  2021        PMID: 34268086      PMCID: PMC8258895          DOI: 10.21037/gs-21-302

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  26 in total

1.  BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer.

Authors:  Zhuoran Liu; Tian Lv; Cong Xie; Zhongmin Di
Journal:  Am J Med Sci       Date:  2018-04-25       Impact factor: 2.378

2.  US-elastography in the differential diagnosis of benign and malignant thyroid nodules.

Authors:  Carmela Asteria; Alessandra Giovanardi; Alessandro Pizzocaro; Luca Cozzaglio; Alberto Morabito; Francesco Somalvico; Adele Zoppo
Journal:  Thyroid       Date:  2008-05       Impact factor: 6.568

3.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

4.  Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules.

Authors:  Erik K Alexander; Jenny P Heering; Carol B Benson; Mary C Frates; Peter M Doubilet; Edmund S Cibas; Ellen Marqusee
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

5.  Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III.

Authors:  Mazen E Iskandar; Giovanni Bonomo; Vaidehi Avadhani; Mark Persky; David Lucido; Beverly Wang; Jennifer L Marti
Journal:  Surgery       Date:  2015-01-26       Impact factor: 3.982

6.  A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells.

Authors:  Naomi Hayashida; Hiroyuki Namba; Atsushi Kumagai; Tomayoshi Hayashi; Akira Ohtsuru; Masahiro Ito; Vladimir A Saenko; Shigeto Maeda; Takashi Kanematsu; Shunichi Yamashita
Journal:  Thyroid       Date:  2004-11       Impact factor: 6.568

7.  BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Authors:  F Frasca; C Nucera; G Pellegriti; P Gangemi; M Attard; M Stella; M Loda; V Vella; C Giordano; F Trimarchi; E Mazzon; A Belfiore; R Vigneri
Journal:  Endocr Relat Cancer       Date:  2008-03       Impact factor: 5.678

8.  Risk of thyroid cancer based on thyroid ultrasound imaging characteristics: results of a population-based study.

Authors:  Rebecca Smith-Bindman; Paulette Lebda; Vickie A Feldstein; Dorra Sellami; Ruth B Goldstein; Natasha Brasic; Chengshi Jin; John Kornak
Journal:  JAMA Intern Med       Date:  2013-10-28       Impact factor: 21.873

9.  Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.

Authors:  Xingyun Su; Xiaoxia Jiang; Xin Xu; Weibin Wang; Xiaodong Teng; Anwen Shao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

10.  Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield.

Authors:  Ashley E Brown; Khin Sandar Lim; George Corpus; Martha T Hustek; Tien Anh N Tran; Chung-Che Chang
Journal:  Cytojournal       Date:  2017-02-24       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.